Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept versus placebo for transfusion-dependent anemia in lower-risk myelodysplastic syndromes with ring sideroblasts
2015-003454-41Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of luspatercept in myelodysplastic syndrome (MDS), anaemia, sponsored by Celgene Corporation. Started Nov 2015; status: completed.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)anaemia
Beyond the preview
Go deeper on 2015-003454-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003454-41.